meglumine has been researched along with n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaddeo, G; Calderaro, J; Chalaye, J; Galletto Pregliasco, A; Itti, E; Kharrat, R; Kobeiter, H; Laurent, A; Legou, F; Luciani, A; Mulé, S; Regnault, H; Tacher, V; Tenenhaus, A | 1 |
1 other study(ies) available for meglumine and n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium
| Article | Year |
|---|---|
Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Choline; Contrast Media; Disease-Free Survival; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Neoplasm Staging; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Recurrence; Retrospective Studies | 2020 |